XTLB - XTL BIOPHARMACEUTICALS LTD
Previous close
2.44
0 0%
Share volume: 0
Last Updated: Fri 20 Dec 2024 05:26:37 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
0.46%
PREVIOUS CLOSE
CHG
CHG%
$2.44
-0.95
0.64%
Fundamental analysis
15%
Profitability
25%
Dept financing
2%
Liquidity
50%
Performance
0%
Performance
5 Days
-7.99%
1 Month
-23.40%
3 Months
-40.50%
6 Months
-36.56%
1 Year
59.96%
2 Year
24.97%
Key data
Stock price
$2.44
DAY RANGE
$1.49 - $2.44
52 WEEK RANGE
$0.81 - $4.99
52 WEEK CHANGE
$59.96
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
Company detail
CEO: Shlomo S. Shalev
Region: US
Website: xtlbio.com
Employees: 8
IPO year: -
Issue type: American Depository Receipt (ADR’s)
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: xtlbio.com
Employees: 8
IPO year: -
Issue type: American Depository Receipt (ADR’s)
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
The company's lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. XTL Biopharmaceuticals Ltd. is headquartered in Ramat Gan, Israel.
Recent news